TABLE 1.
Clinical Characteristics of the Study Cohort Prior to Salvage Therapy With Salvage Treatment Details (N=25)
| Median Initial PSA in ng/ml (range) | 7.45 (4.2 to 18.4) |
| #PSA 0 to <4 (%) | 0 (0%) |
| #PSA 4 to <10 (%) | 23 (92%) |
| #PSA 10 to 20 (%) | 2 (8%) |
| Initial Gleason Score | |
| # Gleason 2+3=5 (%) | 1 (4%) |
| # Gleason 3+3=6 (%) | 18 (72%) |
| # Gleason 3+4=7 (%) | 6 (24%) |
| Initial Clinical T-Category | |
| #T1c (%) | 17 (68%) |
| #T2a (%) | 7 (28%) |
| #Unknown (%) | 1 (4%) |
| Initial Radiation Treatment Received | |
| #External Beam Radiation (66–70.2Gy) | 12 (48%) |
| #Brachytherapy (137 Gy, MRI-Guided) | 11 (44%) |
| #External Beam + Brachytherapy | 1 (4%) |
| #External beam + Hormones (4 months) | 1 (4%) |
| Median Pre-Salvage PSA Doubling Time (range) | 9.46 months (1.9 to 39.9) |
| #PSADT < 3 months (%) | 2 (8%) |
| #PSADT 3 to <6 months (%) | 5 (20%) |
| #PSADT 6 to <12 months (%) | 10 (40%) |
| #PSADT ≥12 months (%) | 8 (32%) |
| Median Interval Between Radiation Treatments | 5.2 years (2.5 to 12.8) |
| #<2 years (%) | 0 (0%) |
| #2 to <5 years (%) | 10 (40%) |
| #5 to <10 years (%) | 13 (52%) |
| #≥10 years (%) | 1 (4%) |
| Median Age in years at Salvage (range): | 65 years (56 to 82) |
| ECOG Performance Status | |
| 0 | 25 (100%) |
| 1 | 0 (0%) |
| 2 | 0 (0%) |
| Median PSA in ng/ml at Salvage (range) | 5.5 (1.4 to 11.6) |
| #PSA 0 to <4 (%) | 9 (36%) |
| #PSA 4 to 10 (%) | 15 (60%) |
| #PSA 10 to 20 (%) | 1 (4%) |
| Median number of salvage needles (range) | 20 (13–26) |
| Median total salvage activity (range) | 26.3 mCi (21.2–43.0) |
| Median salvage gland size (range) | 21 cc (12–66) |
| Median salvage activity/cc (range) | 1.18 (0.59–2.0) |